Fluxion Biosciences has announced that it has launched its BioFlux Quattro High Throughput Array System for physiologically relevant live cell analysis. The system is now commercially available and shipping to customers.
The Quattro Array system is sold as a separate component and can expand the capabilities of any existing BioFlux 200 or BioFlux 1000/1000z system. The Quattro Array runs up to 4 BioFlux plates at the same time.
Plates can be read by a microscope or High Content Screening system as a time-point or end-point assay. The increased throughput is especially valuable for lead optimization applications where the ability to closely simulate in vivo conditions is critical to identifying the best candidates for clinical development.
Introduced 5 years ago, the BioFlux system provides the ability to emulate physiological flow and shear forces in an in vitro model, while retaining the industry standard well plate format.
The system allows the execution of a multitude of assays requiring precise manipulation of the cellular micro-environment, including control of liquid composition, oxygen content, temperature, and shear.
Providing a much better approximation of in vivo conditions than traditional static well plate assays, BioFlux is becoming a standard in drug development and is used in many leading pharmaceutical companies such as Sanofi-Aventis, Actelion, Pfizer, Amgen, BMS, Merck, Bayer, Genentech, and many others.
“With the introduction of the BioFlux Quattro Array, we provide new and existing customers the ability to expand the throughput of their assays where physiologically-relevant conditions are required” said Jeff Jensen, CEO of Fluxion Biosciences.
Jensen continued, “Anti-platelet, anti-microbial, cancer, and anti-inflammatory drugs (to name a few) are examples of applications where drug response is affected by the environment around the cells. In these and many other drug applications, drug activity modulates, or is affected by, cellular responses caused by mechanical stress, dissolved gas concentration, or drug delivery profiles. With its unique capability to mimic conditions in the body, now at even higher throughput, the BioFlux system with the Quattro Array is a significant advance for drug development.”